scholarly journals Vitamin D levels in patients with chronic hepatitis B

Hepatology ◽  
2014 ◽  
Vol 60 (2) ◽  
pp. 768-768 ◽  
Author(s):  
Cumali Efe ◽  
Tugrul Purnak ◽  
Ersan Ozaslan
2015 ◽  
Vol 63 (5) ◽  
pp. 1086-1092 ◽  
Author(s):  
Henry Lik-Yuen Chan ◽  
Magdy Elkhashab ◽  
Huy Trinh ◽  
Won Young Tak ◽  
Xiaoli Ma ◽  
...  

2019 ◽  
Vol 25 (2) ◽  
pp. 2553-2558
Author(s):  
Biljana Ilkovska ◽  
◽  
Bisera Kotevska-Trifunova ◽  
Sandra Hristovska ◽  
Marina Ivanovska ◽  
...  

Gut ◽  
2011 ◽  
Vol 60 (Suppl 2) ◽  
pp. A15-A16
Author(s):  
H.-L. Nguyen ◽  
Carey ◽  
M. A. B. Al-Freah ◽  
D. Joe ◽  
R. Sherwood ◽  
...  

2011 ◽  
Vol 140 (5) ◽  
pp. S-932 ◽  
Author(s):  
Katherine Small ◽  
Marion-Anna Protano ◽  
Douglas T. Dieterich ◽  
Marie-Louise C. Vachon

Author(s):  
Amal Ahmed Mohamed ◽  
Sabry Abdo ◽  
Ebada Said ◽  
Waleed El Agawy ◽  
Peter Awad ◽  
...  

Background & Aims: Hepatitis B is a potentially life-threatening liver infection and it is a major global health problem. Over the past decade, numerous studies have reported that patients with CLD, especially HCV-positive and HBV-positive patients, have decreased 25(OH) D levels. The current study was designed to assess the serum levels of vitamin D [25(OH) D3] in chronic hepatitis B patients, before and during treatment with antiviral therapy. Methods: It was a prospective study in which 80 subjects were enrolled between December 2017 and June 2018. A total of 50 treatment-naïve chronic HBV patients and 30 healthy subjects were recruited. The studied cases received treatment in the form of Lamivudine 100 mg tablet, once daily. Full routine laboratory investigations, HBV DNA measurement by real time PCR; once before initiation of antiviral treatment and again at least 6 months later, serum vitamin D level [25(OH)D3; assessed twice, once before initiation of antiviral treatment and again at least 6 months later; were done for all the patients enrolled in the study. Results: The studied cases showed a significantly low mean serum Vitamin D level when assessed before treatment (21.6 ± 5.8 ng/ml), compared to the level after 6 ms of treatment (31.1 ± 7.3 ng/ml) that was comparable to that of the control group (33.4 ± 5 ng/ml). Conclusion: The present study highlights the impact of antiviral therapy on vitamin D deficiency in CHB patients, where an effective therapy improves vitamin D levels. Meanwhile it is recommended to study the impact of vitamin D replacement and correction on the disease progression or regression.


2016 ◽  
Vol 10 (09) ◽  
pp. 1025-1030 ◽  
Author(s):  
Huijuan Zhu ◽  
Xingxiang Liu ◽  
Yi Ding ◽  
Hui Zhou ◽  
Yiying Wang ◽  
...  

Introduction: Vitamin D is significantly associated with virus replication in chronic hepatitis B virus (HBV) infection. However, the relationship between low serum vitamin D levels and HBV “a” determinant mutations remains unknown. Methodology: A total of 133 chronically HBV-infected, treatment-naive patients were randomly selected in the present study. Serum vitamin D levels were measured by using liquid chromatography-mass spectrometry. The HBV “a” determinant was amplified, sequenced, and analyzed by nested polymerase chain reaction (PCR). Results: Among 133 patients, 36, 88, and 9 patients had vitamin D deficiency (25(OH)D < 14 ng/mL), vitamin D insufficiency (25(OH)D ≥ 14 and < 30 ng/mL), and normal vitamin D serum levels ((25(OH)D ≥ 30 ng/mL), respectively. As results showed, 36 [11 genotype B HBVs (HBV/B) and 25 genotype C HBVs (HBV/C)] were isolated from the vitamin D-deficient group, 88 (48 HBV/B and 40 HBV/C) from the vitamin D-insufficient group, and 4 HBV/C strains from the normal serum-vitamin D group. Compared to the HBV/B infected patients with vitamin D insufficiency, higher rates of amino acid mutation within “a” determinant were detected in HBV/B-infected, vitamin D-deficient patients. Moreover, the change frequency of M133 was 27.27% in HBV/B infected patients with vitamin D deficiency, which was significantly higher than those in the vitamin D-insufficient group (p = 0.040). Conclusions: Vitamin D deficiency is significantly associated with genotype B HBV “a” determinant mutations.


Sign in / Sign up

Export Citation Format

Share Document